Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a progressive inflammatory immune-mediated disorder \[[@CR1]\]. In the United States, approximately 1.36 million adults, comprising 0.6% of the population, are affected by RA \[[@CR2]\]. Fatigue, joint inflammation, pain, and deformities are key complications of RA leading to impaired physical functioning, work productivity, activities of daily living, and compromised overall emotional well-being \[[@CR3]\]. Medications currently recommended for the management of RA in the United States include corticosteroids, conventional disease-modifying antirheumatic drugs (DMARDs), targeted DMARDs, and biologic DMARDs \[[@CR4], [@CR5]\]. Historically, treatment of RA focused on symptom control and pain management. However, the development of new DMARDs including tumor necrosis factor inhibitor (TNFi), which slow clinical and radiographic progression of RA, has changed the paradigm of disease management by making disease remission the treatment goal \[[@CR5]\]. Besides achieving remission or low disease activity, control over symptoms such as pain is of primary importance to many patients with RA \[[@CR6]\]. Pain is often included in assessment tools for measuring disease activity \[[@CR7]\]. However, pain control is an unmet need among RA patients and many patients continue to experience unacceptable levels of pain despite treatment for pain \[[@CR8]\].

Understanding about opioid utilization in the RA population is critical for stakeholders who are involved in disease management of this population. It is estimated that about 40--55% of RA patients utilize opioid analgesics \[[@CR9], [@CR10]\]. Despite its widespread use, the role of opioids in pain management of RA is not well established in clinical guidelines. In a Cochrane review by Whittle et al., the authors concluded that common adverse events may offset the benefits of oral opioids \[[@CR11]\]. Further, use of opioids in RA patients might suggest uncontrolled pain or be indicative of an unmet need in pain control of this population. Finally, there are well-documented risks associated with opioid use including overdose and opioid use disorder \[[@CR12]\]. In studies specific to the RA population, use of opioids increases risks of infection and fracture \[[@CR13], [@CR14]\].

For these reasons, the treatment strategy to reduce opioid use in RA patients is of interest. Newer generations of RA treatments including TNFi have a potential to reduce use of other medications for pain control including opioids. Previous studies have found TNFi agents may have an opioid-sparing effect in patients with RA \[[@CR15], [@CR16]\]. However, understanding of patterns of opioid use in RA patients with TNFi initiation is still limited. The purpose of this analysis was to assess opioid utilization before and after TNFi initiation in a commercially insured population with RA.

Methods {#Sec2}
=======

Data Source and Patient Selection {#Sec3}
---------------------------------

This retrospective cohort study used a 10% random sample of enrollees within the IQVIA™ Health Plan Claims Data between January 1, 2007 and December 31, 2015. The database includes fully adjudicated medical and pharmacy claims from health plans and self-insured employer groups for over 10 million beneficiaries in the United States. The patient identification period is from January 1, 2008 to December 31, 2014. The index date was the date of the first TNFi claim during the patient identification period. TNFi utilization was identified by national drug code or healthcare common procedure coding system codes for etanercept, adalimumab, infliximab, certolizumab, or golimumab. Opioid utilization measures were identified during the 12-month period before (baseline period) and the 12-month period after (follow-up period) TNFi initiation.

Patients eligible for our study had two claims of RA \[International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 714.x except 714.3 and 714.9\] 60 days apart with at least one claim in the baseline period. Study individuals were required to have 12 months of continuous enrollment in the health plan before and after the index date (total enrollment of 24 months). Patients were excluded if: (1) their age at index date was less than 19 years, (2) they had claims for any biologic DMARD therapy in the baseline period, (3) they had claims for cancer or hospice stay during study period. This study was approved by the University of Maryland, Baltimore (UMB) Institutional Review Board. A waiver of consent has been approved per 45 CFR 46.116(d).

Outcome Measures {#Sec4}
----------------

Changes in the opioid utilization before and after TNFi initiation were compared using the following measures:Proportion of patients receiving ≥ 1 opioid prescription.Proportion of patients receiving ≥ 50 mg median daily morphine equivalent dose (MED).

MED was calculated by multiplying opioid strength, quantity, conversion ratio, and dividing the sum by total days supplied.

Statistical Analysis {#Sec5}
--------------------

Statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). The change in proportion of opioid users from pre-index to post-index was assessed using McNemar's Chi-square test to account for correlation due to paired measurements.

Results {#Sec6}
=======

Among 2330 patients who met eligibility criteria, mean age was 51.7 years old and 75% were female (Table [1](#Tab1){ref-type="table"}). A majority of patients had commercial insurance and preferred provider organization as their plan. Among included individuals, 38.8% used opioids throughout the study period, 15.2% discontinued the use in post-index, 12.2% newly initiated during post-index, and 33.8% had no use throughout the study period (Table [2](#Tab2){ref-type="table"}). Among 1259 patients who had opioid use during the pre-index period, 28.1% discontinued. Among 1071 patients who had no opioid use during the pre-index period, 26.5% initiated opioids in the post-index period following TNFi initiation. From pre-index to post-index, the proportion of patients receiving any opioid as well as those who received ≥ 50 mg median daily MED decreased. Any opioid utilization decreased from 54.0% in pre-index to 51.0% in post-index and 50 mg or greater daily MED of opioid utilization decreased from 12.6 to 10.6% (Table [3](#Tab3){ref-type="table"}).Table 1Baseline patient characteristicsVariableAll (*n* = 2330)Age, mean (SD)51.7 (11.0)Sex, *n* (%) Female1749 (75.1) Male581 (24.9)Region, *n* (%) Northeast527 (22.6) Midwest668 (28.7) South877 (37.6) West258 (11.1)Insurance type, *n* (%) Commercial1294 (55.5) Self-insured956 (41.0) Other^a^80 (3.4)Plan type, *n* (%) HMO345 (14.8) PPO1704 (73.2) Other^b^279 (3.4)Comorbidities, *n* (%) COPD376 (16.1) Diabetes309 (13.3) Hypertension892 (38.3) Hypercholesterolemia793 (34.0) Pain^c^997 (42.8) Fracture92 (3.9) Infection232 (10.0) Depression297 (12.7) Anxiety205 (8.8) Cardiovascular events^d^132 (5.7)*HMO* Health Maintenance Organization, *PPO* Preferred Provider Organization, *COPD* chronic obstructive pulmonary disease^a^Medicaid, Medicare advantage, unknown/missing^b^Consumer directed health care, fee-for-service, point of service, unknown/missing^c^Non-arthritis pain^d^Cardiovascular events include myocardial infarction, stroke, angina pectoris, and congestive heart failureTable 2Opioid pattern of use*n* (%)Post-index usePre-index useYesNoTotalYes905 (38.8)354 (15.2)1259 (54.0)No284 (12.2)787 (33.8)1071 (46.0)Total1189 (51.0)1141 (49.0)2330 (100.0)Table 3Change in opioid useMeasurePre-indexPost-index*p* valueProportion of patients receiving any opioid, *n* (%)1259 (54.0)1189 (51.0)0.006Proportion of patients receiving ≥ 50 mg daily MED, *n* (%)293 (12.6)246 (10.6)0.005

Discussion {#Sec7}
==========

This study found a modest 3.0% decrease in overall proportion of patients using opioid after TNFi initiation. Our findings are consistent with previous research, which have found a small overall decrease in the proportion of patients using opioids after DMARD initiation \[[@CR15], [@CR16]\]. However, the decrease may be deemed significant when looking at the patients who were using opioid before TNFi initiation. Further, we found there was a considerable proportion of patients with no opioid use in the pre-index period but initiated them after TNFi initiation. This new opioid initiation post-TNFi may reflect an unmet need in pain management. Pain symptoms in RA could be due to different mechanisms including inflammation, structural joint damage, or central sensitization and residual pain even after RA treatment is possible \[[@CR17]\]. This study provides a more comprehensive examination of opioid use pre- and post TNFi initiation, including overall opioid use, proportion of patients with new opioid use, proportion of those with opioid discontinued, and proportion of patients with high daily MED of opioids. Study findings add to existing knowledge about opioid use in commercially insured RA population, which may behave differently than those populations in previous studies such as Medicare beneficiaries.

Limitations of the study include the lack of data on indications for which opioids were prescribed and the uncertainty of actual use of opioids by patients. Since many patients also had non-arthritis pain, it is possible that they were taking opioids for conditions other than RA. In addition, findings of this study are only generalizable to the commercially insured population in the United States. Disease severity of RA including disease activity or remission is an important factor that we were not able to capture in this study due to unavailability of such clinical information in the claims database.

Conclusions {#Sec8}
===========

Opioid use among patients with RA is prevalent. Lower opioid use following TNFi initiation suggests potential benefits of TNFi in pain control and reduction in opioid use for patients with RA. Newly initiated opioid users after TNFi initiation may reflect an unmet need in pain management due to the complex mechanism of pain in RA or the complex comorbidity profile in these patients.
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